Gerhard Kurlemann

July 22, 2025

Use of cannabidiol for off-label treatment of patients with refractory focal, genetic generalised and other epilepsies

Abstract Background: In randomized controlled trials, add-on cannabidiol (CBD) has been shown to reduce seizure frequency in patients with Lennox-Gastaut…

July 12, 2025

Retrospective Multicenter Chart Review Study of Adjunctive Cannabidiol for Seizures Associated with Lennox–Gastaut Syndrome, Dravet Syndrome and Tuberous Sclerosis Complex

Abstract Introduction: Effectiveness and tolerability of plant-derived highly purified cannabidiol (CBD) in patients with Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS),…

February 6, 2023

Real‐world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study

Abstract Objective: Cannabidiol (CBD) is approved for treatment of Dravet syndrome (DS), Lennox‐Gastaut syndrome (LGS), and tuberous sclerosis complex (TSC).…